The pharmacogenetic testing company doubled its revenue but faces a critical cash crunch, with auditors highlighting material uncertainty about its ability to continue as a going concern.
The healthcare diagnostics company has announced it will release its preliminary results for the year ended 30 June 2025 on 5 December 2025 and will host a live investor presentation on 8 December 2025.
The healthcare company reports on the successful results of a pilot programme for rapid genetic testing to guide antiplatelet therapy in stroke patients.
The healthcare diagnostics company has published an NHS implementation guide for its CYP2C19 genotype testing product, which is used to guide Clopidogrel use in stroke patients.
The healthcare company announces the national roll-out of its genetic testing kit in Scotland, which aims to prevent hearing loss in newborn babies.
The healthcare diagnostics company has agreed terms for a £1 million shareholder loan to strengthen its working capital position.
The point-of-care diagnostics company has implemented its MT-RNR1 ID Kit at a hospital in Dublin, further expanding the reach of its pharmacogenetic testing technology.
The healthcare diagnostics company has announced discussions with a major shareholder regarding a potential loan of up to £1 million, though details are still to be finalized.
The healthcare diagnostics company has announced a change in director shareholdings.
The point of care diagnostics company has signed an MOU with the Saudi Ministry of Health to pilot its Genedrive® MT-RNR1 ID Kit under the Generations Hear programme.